Table 3 Summary of freedom from biochemical failure (FFBF) and toxicity with various radiation modalities used to treat high risk prostate cancer
Author | Year | Modality | FFBF | GU toxicity (G2-3) | GI toxicity (G2-3) |
|---|---|---|---|---|---|
Zelefsky [27] | 2006 | IMRT (81 Gy in 45 fx) | 62% | 15% | 3% |
Kupelian [8] | 2007 | IMRT (70 Gy in 28 fx) | 69% | 5.20% | 4.40% |
Zelefsky [31] | 2011 | EBRT + LDR boost | 58% | 17.80% | 6.20% |
Potters [28] | 2005 | EBRT + LDR boost | 63% | 15.80% | 6.60% |
Galalae [29] | 2004 | EBRT + HDR boost | 69% | 23% | 4.10% |
Demanes [30] | 2005 | EBRT + HDR boost | 69% | 7.70% | 2% |